Login Register Cart 0
Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

A Novel Tumor Hypoxia Imaging Agent: [99mTc]Tc(CO)3-CPA-2-NIM

Author(s): Xiao Lin, Xiaojie Tan, Fengyu Wu and Qian Yu*

Volume 16, Issue 4, 2023

Published on: 28 April, 2023

Page: [300 - 307] Pages: 8

DOI: 10.2174/1874471016666230320144641

Price: $65

Abstract

Introduction: Hypoxia imaging agents can selectively remain in hypoxic tissue, which can directly reflect the location and degree of hypoxia.

Methods: Synthesized a novel tumor hypoxia imaging probe [99mTc]Tc(CO)3-CPA-2-NIM and evaluated its biological behavior with the purpose to assess its possibility of becoming a qualified tumor hypoxia imaging agent.

Results: Radiochemcial purity of [99mTc]Tc(CO)3-CPA-2-NIM was greater than 95% after HPLC purification. Lipophilicity coefficient of this complex was -1.74 ± 0.10 (n = 5, number of experiments), indicating it was a hydrophilic complex. In vitro cell experiments demonstrated that this complex has selectivity for hypoxia at oxygen concentrations < 10 ppm (parts per million). Biodistribution experiment in S180 tumor bearing mice showed that tumor uptake reached its highest at 2 h post-injection with mice tumor-to-muscle ratio.

Conclusions: Complex [99mTc]Tc(CO)3-CPA-2-NIM has the possibility of becoming a tumor hypoxia imaging agent.

« Previous Next »
Graphical Abstract

[1]
Böğürcü, N.; Seidel, S.; Garvalov, B.K.; Acker, T. Analysis of hypoxia and the hypoxic response in tumor xenografts. Methods Mol. Biol., 2018, 1742, 283-300.
[http://dx.doi.org/10.1007/978-1-4939-7665-2_25] [PMID: 29330809]
[2]
Chu, T.; Hu, S.; Wei, B.; Wang, Y.; Liu, X.; Wang, X. Synthesis and biological results of the technetium-99m-labeled 4-nitroimidazole for imaging tumor hypoxia. Bioorg. Med. Chem. Lett., 2004, 14(3), 747-749.
[http://dx.doi.org/10.1016/j.bmcl.2003.11.017] [PMID: 14741282]
[3]
Wang, H.; Xu, H. Advances in the study of tumor hypoxia imaging agents. Int. J. Radiol. Nuclear Med., 2012, 36(6), 366-370.
[4]
Yu, Q.; Wang, Z.; Chen, C. Summary and prospect of nitroimidazole PET tumor hypoxia imaging agents. Nuclear Radiol. Chem., 2015, 37(6), 385-389.
[5]
Reischl, G.; Dorow, D.S.; Cullinane, C.; Katsifis, A.; Roselt, P.; Binns, D.; Hicks, R.J. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results. J. Pharm. Pharm. Sci., 2007, 10(2), 203-211.
[PMID: 17706178]
[6]
Wang, S.; Li, Y. Tumor hypoxia imaging agent 18F-FMISO clinical research progress. Chinese J. Clin. Med. Imag., 2018, 29(1), 58-60.
[PMID: 33757460]
[7]
Luo, Z.; Zhu, H.; Lin, X. The use of tumor PET oxygen imaging agents and radiotherapy for hypoxia sensitization. Int. J. Oncol., 2014, 41(7), 507-511.
[8]
Hayashi, K.; Furutsuka, K.; Takei, M.; Muto, M.; Nakao, R.; Aki, H.; Suzuki, K.; Fukumura, T. High-yield automated synthesis of [18F]fluoroazomycin arabinoside ([18F]FAZA) for hypoxia-specific tumor imaging. Appl. Radiat. Isot., 2011, 69(7), 1007-1013.
[http://dx.doi.org/10.1016/j.apradiso.2011.02.025] [PMID: 21420304]
[9]
Gammon, S.T.; Pisaneschi, F.; Bandi, M.L.; Smith, M.G.; Sun, Y.; Rao, Y.; Muller, F.; Wong, F.; De Groot, J.; Ackroyd, J.; Mawlawi, O.; Davies, M.A.; Vashisht Gopal, Y.N.; Di Francesco, M.E.; Marszalek, J.R.; Dewhirst, M.; Piwnica-Worms, D. Mechanism-specific pharmacodynamics of a novel complex-1inhibitor quantified by imaging reversal of consumptive hypoxia with [18F]FAZA PET in vivo. Cells, 2019, 8(12), 1487.
[http://dx.doi.org/10.3390/cells8121487]
[10]
Wack, L.J.; Mönnich, D.; van Elmpt, W.; Zegers, C.M.L.; Troost, E.G.C.; Zips, D.; Thorwarth, D. Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia – a simulation study. Acta Oncol., 2015, 54(9), 1370-1377.
[http://dx.doi.org/10.3109/0284186X.2015.1067721] [PMID: 26203928]
[11]
Dubois, L.; Landuyt, W.; Cloetens, L. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36(2), 209-218.
[PMID: 8274515]
[12]
Linder, K.E.; Chan, Y.W.; Cyr, J.E. Synthesis, characterization, and in vitro evaluation of nitroimidazole-BATO complexes: New technetium compounds designed for imaging hypoxic tissue. Bioconjug. Chem., 1993, 4(5), 326-333.
[PMID: 8274515]
[13]
Okada, R.D.; Nguyen, K.N.; Strausse, H.W.; Johnson, G., III Effects of low flow and hypoxia on myocardial retention of technetium-99m BMS181321. Eur. J. Nucl. Med., 1996, 23(4), 443-447.
[http://dx.doi.org/10.1007/BF01247374] [PMID: 8612666]
[14]
Melo, T.; Duncan, J.; Ballinger, J.R.; Rauth, A.M. BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors. J. Nucl. Med., 2000, 41(1), 169-176.
[15]
Alberto, R.; Schibli, R.; Egli, A.; Schubiger, A.P.; Abram, U.; Kaden, T.A. A novel organometallic aqua complex of technetium for the labeling of biomolecules: Synthesis of (99mTc(CO)3(H2O)3)+ from (99mTcO44-) in aqueous solution and its reaction with a bifunctional ligand. J. Am. Chem. Soc., 1998, 120(31), 7987-7988.
[http://dx.doi.org/10.1021/ja980745t]
[16]
Mallia, M.B.; Subramanian, S.; Banerjee, S.; Sarma, H.D.; Venkatesh, M. Evaluation of 99mTc(CO)3 complex of 2-methyl-5-nitroimidazole as an agent for targeting tumor hypoxia. Bioorg. Med. Chem., 2006, 14(23), 7666-7670.
[http://dx.doi.org/10.1016/j.bmc.2006.08.011] [PMID: 16949291]
[17]
Wang, Y.; Zhu, J.; Song, X.; Wang, X.; Yang, J.; Zhang, J. Synthesis and evaluation of 99mTc–2-[(3-carboxy-1-oxopropyl)amino]-2-deoxy-d-glucose as a potential tumor imaging agent. Bioorg. Med. Chem. Lett., 2014, 24(16), 3882-3885.
[http://dx.doi.org/10.1016/j.bmcl.2014.06.051] [PMID: 25001483]
[18]
Zhang, J.; Ren, J.; Lin, Y. 99mTc(CO)3-MECHDTC complex preparation and its biodistribution. J. Beijing Normal Univ., 2007, 43(3), 423-426.
[19]
Zhang, J.; Yu, Q.; Huo, J.; Pang, Y.; Yang, S.; He, Y.; Tang, T.; Yang, C.; Wang, X. Synthesis and biodistribution of a novel 99mTc-DMSA-metronidazole ester as a potential tumor hypoxia imaging agent. J. Radioanal. Nucl. Chem., 2010, 283(2), 481-485.
[http://dx.doi.org/10.1007/s10967-010-0455-2]
[20]
Zhang, Y.; Chu, T.; Gao, X.; Liu, X.; Yang, Z.; Guo, Z.; Wang, X. Synthesis and preliminary biological evaluation of the 99mTc labeled nitrobenzoimidazole and nitrotriazole as tumor hypoxia markers. Bioorg. Med. Chem. Lett., 2006, 16(7), 1831-1833.
[http://dx.doi.org/10.1016/j.bmcl.2006.01.001] [PMID: 16460938]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy